BioSpace: Biotech, Pharmaceutical and Clinical Research News
网页Boehringer, Insilico Appear to Break Through Against IPF. Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary fibrosis, an intractable lung disease for which current treatment options fail to stop progression, but the data were limited, leaving experts wanting. September 24, 2024.
News - BioSpace
网页Tristan Manalac. BIOSECURE Act. The Financial Times reported Thursday that WuXi AppTec is looking to sell its cell and gene therapy manufacturing unit, with facilities in Philadelphia, while WuXi Biologics wants to offload some of its production sites in Europe. October 3, 2024.
China - BioSpace
网页Well-financed startup Tome is winding down operations just as two new companies, Borealis Biosciences and GondolaBio, are launching. Meanwhile, in the midst of already tense relations with China, House lawmakers raise the alarm about U.S. companies working with the country’s military on trials. August 28, 2024. ·.
Latest News & Press Releases - BioSpace
网页2024年10月1日 · Halda Therapeutics Raises $126M in Series B Extension to Advance Two Cancer Candidates. The Connecticut-based biotech, which emerged from stealth last year, has secured $202 million to date as it looks to move two assets targeting prostate and breast cancer into the clinic. August 12, 2024. ·. 2 min read.
About Us - BioSpace
网页About Us. BioSpace is the hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. The proprietary resources we provide help companies make informed decisions regarding their workforce.
All News - BioSpace
网页FDA Approves New Oral Alzheimer’s Therapy, Expands Label for Grifols’ SCIg Therapy. In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA’s decisions in 2024. July 29, 2024. ·.
Approvals - BioSpace
网页2024年9月23日 · Sanofi Secures First-Line Nod for Sarclisa in Multiple Myeloma, Tees Up Competition With J&J. With Friday’s approval, Sanofi’s anti-CD38 antibody Sarclisa will go head-to-head with the first such therapy for multiple myeloma, Johnson & Johnson’s Darzalex, which raked in nearly $10 billion last year. September 23, 2024.
FDA News: Approvals, Adcomms, Complete Response Letters and ... - BioSpace
网页Approvals. Adcomms. Complete response letters. Guidances. FDA. FDA Tracker: J&J Scores Third NSCLC Approval for Rybrevant This Year. In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA’s decisions in 2024. September 20, 2024.
Asia - BioSpace
网页House Speaker Plans to Vote, Pass BIOSECURE Act into Law This Year. House Speaker Mike Johnson (R-La.) on Monday said he intends to have a “significant package of China-related legislation” signed into law by the end of this year, including the BIOSECURE Act which intends to stop federal contracts with Chinese “companies of concern ...
Clinical research - BioSpace
网页2024年8月12日 · Pelage Pharmaceuticals Advances Clinical Program with First Patients Dosed in Phase 2 Study for Hair Loss and GV-Led $14M Series A-1. August 13, 2024. 4 min read. Sionna Therapeutics Announces Initiation of Two Phase 1 Clinical Trials of SION-719 and SION-451, in Development for Cystic Fibrosis.